iStent trabecular micro-bypass stent for open-angle glaucoma

This article was published in the following Dove Press journal:
Clinical Ophthalmology
23 September 2014
Number of times this article has been viewed

Abstract: Trabecular micro-bypass stents, commonly known as iStents, are micro-invasive glaucoma surgery (MIGS) devices used to treat open-angle glaucoma. Like other MIGS procedures that enhance trabecular outflow, the iStent lowers intraocular pressure (IOP) by creating a direct channel between the anterior chamber and Schlemm’s canal. iStents are typically implanted at the time of phacoemulsification for patients with open-angle glaucoma and visually significant cataracts. This review summarizes the published data regarding the efficacy, safety, and cost considerations of trabecular micro-bypass stents. Most studies found statistically significant reductions in mean IOP and ocular medication use after combined phacoemulsification with single or double iStent implantation. The devices were found to be very safe, with a safety profile similar to that of cataract surgery. Complications were infrequent, with the most common complications being temporary stent obstruction or malposition, which resolved with observation or secondary procedures. Future studies are needed to evaluate long-term outcomes, patient satisfaction, cost effectiveness, and expanded indications.

Keywords: iStent, trabecular micro-bypass, glaucoma, MIGS, ab interno, surgery

Introduction
The worldwide prevalence of open-angle glaucoma is 60.5 million.1 Traditionally, treatment for glaucoma has included topical hypotensive medications, laser therapy, and surgery. Patient adherence to medication is suboptimal due to common side effects such as ocular surface irritation,2 difficulty of proper application,3 and financial considerations.4 Poor control of glaucoma despite medications and adjuvant laser trabeculoplasty is typically managed with surgical therapy. The traditional full-thickness glaucoma surgeries of trabeculectomy and glaucoma drainage devices effectively lower intraocular pressure (IOP); however, serious complications, including hypotony, choroidal effusions, suprachoroidal hemorrhage, corneal edema, diplopia, and long-term risks of endophthalmitis, accompany these procedures.5 In recent years, the development of a new class of procedures, termed micro-invasive glaucoma surgery (MIGS), has raised excitement within the glaucoma community by offering an alternative form of effective IOP reduction associated with lower medication burden and complication rates.6 Our review focuses on trabecular micro-bypass stents, one of the most widely used MIGS devices. A PubMed search for ‘iStent’ revealed 26 articles. Each of these full-text articles was reviewed. Secondary searches for ‘trabecular bypass’ and ‘MIGS’ identified additional relevant articles. Randomized controlled trials (RCTs), case series, review articles, and cost studies were cited in this paper.

Design
The iStent® (Glaukos Corporation, Laguna Hills, CA, USA) is a first-generation trabecular micro-bypass product. It is a heparin-coated non-ferromagnetic, titanium stent connecting the anterior chamber directly to Schlemm’s canal. With dimensions...
of 1 mm in length and 0.3 mm in height, the iStent is the smallest implantable medical device approved for use in humans by the US Food and Drug Administration.

Using gonioscopy, the device can be visualized within Schlemm’s canal and in the anterior chamber, allowing aqueous to flow between these two spaces. Perpendicular to the inlet, the longer pointed end facilitates entry into Schlemm’s canal, and the three retention arches secure its position.\(^7,8\) The half-cylinder profile with an open posterior wall prevents blockage or fibrosis over the tip\(^5,9\) (Figures 1, 2, and 3). The inserter consists of 26-gauge tubing and four finger extensions. This design facilitates device implantation via a clear corneal incision and ab interno approach under gonioscopy.\(^9\) These extensions also allow re-grasping of the device if further manipulation or repositioning is necessary.

A second-generation model, the iStent inject\(^8\) (Glaukos Corporation, Laguna Hills, CA, USA), has been certified in Europe.\(^11\) It is similarly composed of titanium, and is only 360 microns in length, smaller in size than the first-generation iStent. Its shape is characterized by an apical head, 230 microns in width, containing four inlets for the passage of aqueous. The narrow body contains the lumen and sits within the trabecular meshwork. A flange secures the device on the inner wall of the meshwork, allowing aqueous to exit into Schlemm’s canal (Figures 4, 5, and 6). A 23-gauge stainless steel insertion sleeve covers the injector, which comes preloaded with two stents.\(^12\) This newer model has the advantage of easier surgical technique; no sideways sliding of the stent is required for positioning, and two devices can be implanted with a single inserter without exiting and re-entering the eye.

**Surgical technique**

If combined with phacoemulsification, iStent implantation is performed using the same clear corneal incision. If the iStent is implanted without phacoemulsification, a clear corneal incision of 1.5–2 mm is performed temporally. An ophthalmic viscoelastic device (OVD) is used to inflate the anterior chamber and widen the nasal angle. After rotating the head of the patient 30° away from the surgeon, and the oculars of the surgical microscope 30° towards the surgeon, the iStent inserter crosses the anterior chamber and approaches the nasal angle under direct gonioscopic view. The iStent punctures the trabecular meshwork and slides into Schlemm’s canal. The OVD is then rinsed out of the anterior chamber unless phacoemulsification follows.

The authors’ preference is to perform iStent implantation prior to phacoemulsification because the view through the cornea is more likely to be clear, the sclera is less hydrated and its rigidity is more favorable for iStent implantation, and potential complications of phacoemulsification do not affect iStent implantation. Some surgeons favor performing iStent implantation following phacoemulsification because the angle is wider and the anterior capsule is less at risk of inadvertent breach. However, it is worth noting that, in patients with open-angle glaucoma, a significant opening of the angle can be achieved with OVD prior to phacoemulsification.

---

**Figure 1** First-generation iStent.  

**Figure 2** Applicator for the first-generation iStent.  
**Notes:** Reprinted from Minckler DS, Hill RA. Use of novel devices for control of intraocular pressure. Exp Eye Res. 2009;88(4):792–798. Copyright © 2009, with permission from Elsevier.\(^10\)

**Figure 3** Gonioscopic view of the angle with three implanted iStents into the trabecular meshwork.  
**Notes:** Copyright © 2012. Reproduced with permission from Lippincott Williams & Wilkins/Wolters Kluwer Health, from: Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23(2):96–104. Promotional and commercial use of the material in print, digital or mobile device format is prohibited without the permission from the publisher Lippincott Williams & Wilkins. Please contact journalpermissions@lww.com for further information.
Other aspects of iStent implantation that can optimize the success of the procedure are important to consider. Wounds should be slightly anterior to the limbus to avoid limbal vessels and bleeding that could impair the quality of the gonioscopic view. OVD under-filling could contribute to a soft eye that easily develops corneal folds under gonioscopic view. However, an overfilled eye can lead to a flattened Schlemm’s canal. The approach to entry into Schlemm’s canal should be similar to venipuncture: a sharper initial approach to puncture the trabecular meshwork followed by a flattened approach to slide into Schlemm’s canal without abutting against the outer wall of Schlemm’s canal. Like venipuncture, there should be no resistance throughout the insertion of the iStent. Any torque of the eye during the insertion of the iStent is likely due to the iStent abutting against the outer wall of Schlemm’s canal (sclera); the authors suggest backing up the iStent and flattening the approach of the iStent in that case until no torque or resistance occurs during the insertion. Furthermore, any

Figure 4 Second-generation iStent inject.

Figure 5 Various scanning electron microscope views of the iStent inject positioned within the trabecular meshwork (TM) and Schlemm’s canal (SC) in human anterior segment culture.

Figure 6 Three-dimensional micro-computed tomography views showing dilatation of Schlemm’s canal (SC) after implantation of the iStent inject, in relation to the trabecular meshwork (TM) and sclera (SL).
intracameral bleeding can be cleared using an OVD. Blood reflux from the iStent is normal and can signify that the trabecular outflow system is patent. Prior to moving on to the next step of surgery, it is critical to ensure the proper positioning of the iStent within Schlemm’s canal.

The implantation of the second-generation micro-bypass stent (iStent inject) shares many features of the first-generation stent. The difference lies in the uni-dimensional aspect of its insertion. Once the trabecular meshwork is punctured by the sharp tip of the inserter, the stent is released into Schlemm’s canal, so that sideways sliding is not required. Furthermore, two stents can be implanted with the same inserter.

Mechanism of action
By creating and maintaining a channel between the aqueous in the anterior chamber and Schlemm’s canal, the iStent bypasses the site of highest resistance to aqueous outflow: the juxtacanalicular trabecular meshwork.13 Flow rates and resistance through the devices have been studied in ex vivo models. Hunter et al14 found that a single iStent reduced total outflow resistance by 30% and IOP by 6 mmHg, using a human whole eye perfusion model, computational fluid dynamics, and the Hagen–Poiseuille equation. Two stents decreased resistance by 44% and IOP by 8.9 mmHg from baseline.14 Using anterior segment perfusion models, Bahler et al15 found similar drops in IOP of 6.1 mmHg with one iStent and 9.7 mmHg with two. They repeated the protocol for the iStent inject, which increased outflow facility from 0.16 to 0.38 μL/min/mmHg with one device and 0.78 μL/min/mmHg with two.12 These results suggested that the IOP-lowering effect could be titrated with the number of implants.

Efficacy
A number of clinical studies from the past decade have examined the efficacy of the iStent and iStent inject. A summary of these RCTs and case series can be found in Table 1. Looking at the three RCTs and seven case series that examined the efficacy of single or multiple iStents with or without phacoemulsification, IOP reduction ranged from 16% to 33%, and medication reduction ranged from 0.5 to 2.0 agents, as seen in Table 1. With respect to the iStent inject with or without phacoemulsification, only two case series have been published. Listed in Table 1, both studies implanted two stents and found that IOP decreased almost 40% and medication decreased by one agent. The individual studies are described in the following sections.

| Table 1 Summary of trabecular micro-bypass clinical studies |
|---|---|---|---|---|---|---|
| Authors | Design | Site | n | Glaucoma type | Procedure | Years | IOP reduction | Medication reduction | Washout |
| iStent | Craven et al14 | RCT | USA | 116 | POAG, PDG, PXG | 1 stent + phaco | 2 | 8 mmHg, 33% | 1.3 | Yes |
| Samuelson et al15 | RCT | USA | 111 | POAG, PDG, PXG | 1 stent + phaco | 1 | 8 mmHg, 33% | 1.4 | Yes |
| Fea16 | RCT | Italy | 12 | POAG | 1 stent + phaco | 1.25 | 3 mmHg, 17% | 1.6 | Yes |
| Fernández-Barrientos et al17 | RCT | Spain | 17 | POAG, OHT | 2 stents + phaco | 1 | 7 mmHg, 27% | 1.1 | Yes |
| Belovay et al18 | Series | Canada | 53 | POAG, PXE, mixed | 2–3 stents + phaco | 1 | 4 mmHg, 20% | 2.0 | No |
| Spiegel et al19 | Series | Europe | 48 | POAG, PDG, PXG | 1 stent + phaco | 1 | 4 mmHg, 18% | 1.2 | No |
| Arriola-Villalobos et al20 | Series | Spain | 19 | POAG, PDG, PXG | 1 stent + phaco | 5 | 3 mmHg, 16% | 0.5 | No |
| Vandewalle et al21 | Series | Belgium | 10 | POAG, PXG | 1 stent ± phaco | 1 | 4 mmHg, 19% | 1.0 | No |
| Patel et al22 | Series | UK | 44 | POAG, PXG, recession | 1 stent ± phaco | 0.5 | 4 mmHg, 21% | 1.2 | No |
| Buchacra et al23 | Series | Spain | 10 | PDG, PXG, trauma, steroid | 1 stent | 1 | 7 mmHg, 27% | 1.1 | No |
| iStent inject | Arriola-Villalobos et al24 | Series | Spain | 20 | POAG, PXG, OHT | 2 stents + phaco | 1 | 9 mmHg, 36% | 1.0 | Yes |
| Voskanyan et al25 | Series | Europe | 99 | POAG, PDG, PXG | 2 stents | 1 | 10 mmHg, 40% | 2.0 | Yes |

Note: The numerical value listed under ‘Medication Reduction’ represents the decrease in mean number of hypotensive agents used after the intervention.

Abbreviations: IOP, intraocular pressure; OAG, open-angle glaucoma; OHT, ocular hypertension; PDG, pigment-dispersion glaucoma; phaco, phacoemulsification; POAG, primary open-angle glaucoma; PXG, pseudoexfoliation glaucoma; RCT, randomized controlled trial.
Trabecular stent with phacoemulsification: RCTs

The efficacy of the iStent was studied in a prospective, multicenter RCT that measured IOP reduction and medication use in patients with concurrent cataracts and mild to moderate open-angle glaucoma. Across 29 centers, 240 eyes with cataract and primary open angle glaucoma (POAG), pseudoexfoliation glaucoma (PXG), or pigment-dispersion glaucoma (PDG) were randomized to phacoemulsification alone (control group) or combined phacoemulsification with one iStent (treatment group). Inclusion criteria included best corrected visual acuity (BCVA) of 20/40 or worse, IOP \( \leq 24 \) mmHg while taking one to three ocular hypotensive medications, and IOP between 22 and 36 mmHg after washout of glaucoma medications. The primary efficacy outcome was the proportion of patients with mouth 12 IOP \( \leq 21 \) mmHg without medications. This was achieved by 72% of the iStent group versus 50% of the phacoemulsification alone group after 1 year \((P<0.001)\). The secondary outcome was unmedicated month 12 IOP reduction \( \geq 20\% \) from baseline, which was seen in 66% of treated versus 48% of control eyes \((P<0.003)\). The mean reduction in IOP was 30% or 8 mmHg in both groups at 12 months. This was expected because the protocol called for subjects to be managed to an IOP of 21 mmHg or lower regardless of treatment group, through the use of glaucoma medications. At 12 months, Samuelson et al found that 15% of patients who received the iStent with phacoemulsification were using medications compared with 35% of controls \((P=0.001)\) (Table 1, row 2).

Results at 2 years by Craven et al showed relatively similar outcomes, as seen in Table 1, row 1. Although the study was neither designed nor statistically powered to include 2-year efficacy endpoints, 61% of treated versus 50% of control eyes had month 24 IOP \( \leq 21 \) mmHg without medications \((P<0.036)\). A total of 53% of treated eyes compared with 44% of control eyes had unmedicated month 24 IOP reduction \( \geq 20\% \) \((P<0.090)\). Overall mean IOP in the stent group was 17.0 mmHg after 1 year and 17.1 mmHg after 2 years, whereas the control group had 17.0 mmHg and 17.8 mmHg during the same time period. However, the difference in ocular hypotensive medication use was no longer statistically significant between groups after 24 months.

Prior to that study, Fea et al performed a prospective, double-masked RCT on 36 Italian patients with cataract and POAG. Inclusion criteria included IOP >18 mmHg, receiving at least one medication, and vision no better than 20/80. Patients received either phacoemulsification alone or in combination with a single iStent (Table 1, row 3). IOP dropped from 17.9 to 14.8 mmHg in the combined group and from 17.3 to 15.7 mmHg in controls at 15 months \((P<0.031)\). This unique study design included a washout of medications at 15 months to remove the confounding effect of glaucoma medications. Following washout at 16 months, IOP was 16.6 mmHg in treated versus 19.2 mmHg in control eyes \((P<0.042)\). The mean number of medications, as well as the proportion of patients receiving medications, was significantly lower in the stent group \((P<0.007)\).

A different prospective RCT used fluorophotometry to compare aqueous flow, trabecular outflow facility, and IOP reduction in 33 eyes with cataract and open-angle glaucoma or ocular hypertension (OHT). This time, two iStents were inserted, along with phacoemulsification, in the treatment arm and compared with phacoemulsification alone. While there were no significant changes in flow following intervention, facility increased 275% and 46% in the treatment and control groups, respectively, \((P<0.02)\) after 12 months. Fernández-Barrientos et al found a corresponding mean IOP reduction of 6.6 mmHg versus 3.9 mmHg \((P<0.002)\) and medication use of 0.0 vs 0.7 \((P<0.007)\) in the stent versus phacoemulsification groups, respectively (Table 1, row 4). This represented a larger relative treatment effect than in single stent plus phacoemulsification studies, which Augustinus and Zeyen estimated to lower IOP by 3–4 mmHg on average in a review.

Trabecular stent with phacoemulsification: case series

Published case series have reported comparable reductions in IOP and medication use after combined phacoemulsification and single stent implantation. In a much earlier study, Spiegel et al performed combined procedures in 58 patients with POAG, PXG, and PDG across four European centers. At baseline, mean IOP was 21.5 mmHg on 1.5 medications. At 6 months, IOP dropped by 25% or 5.7 mmHg \((P<0.001)\), and medications decreased by 1.0 agents \((P<0.001)\). After 1 year, the treatment effect diminished slightly, with IOP reduction of 18% or 4.4 mmHg from baseline \((P<0.001)\); however, the treatment effect of adequate control without medications remained stable, with a reduction of 1.2 agents \((P<0.001)\) as seen in Table 1, row 6. Two-year results are pending. A more recent series of 40 patients with POAG, PXG and angle recession from the UK underwent the same combined treatment. Patel et al reported that after 6 months, IOP decreased by a similar magnitude from 21.1 to 16.7 mmHg \((P<0.01)\), as did the number of drops, from...
IOP fell 40%, and the majority reduced their medication burden by at least two agents (Table 1, row 12).

**Long-term**

The longest reported follow-up period was 5 years in a prospective case series. A total of 19 subjects with cataract, mild to moderate POAG, PXG, or IOP above 18 mmHg underwent cataract surgery with a single iStent. IOP fell 16% from 19.4 to 16.3 mmHg (P=0.002), which appeared stable after 2 years. Medication use also fell from 1.3 to 0.8 (P=0.046), with 42% of subjects off medications entirely (Table 1, row 7). Safety outcomes matched those found in short-term studies, which are discussed in the following section.

**Safety**

The first-generation studies reported consistent safety data with few adverse events. Findings were on par with cataract surgery. In the landmark RCT, both groups had equal rates of vitrectomies, postoperative corneal edema, anterior chamber inflammation, IOP elevation, macular edema, and eventual posterior Nd:YAG (neodymium-doped yttrium aluminum garnet) capsulotomies. In both groups, less than 2% progressed to require a trabeculectomy; over 90% had corrected distance visual acuity of 20/40 or better and stable visual field parameters at 2 years. Case series similarly reported good visual outcomes and no episodes of hypotony, choroidal effusions, or flat chambers.

Most complications related to stent malposition or occlusion early in the postoperative period, affecting 4% to 18% of cases. These resolved with observation or secondary procedures, including Nd:YAG laser, argon laser gonioplasty, recombinant tissue plasminogen activator, stent repositioning, or stent replacement without negative sequelae. Within the first postoperative week, hyphema also occurred in a couple of case series. Intraoperatively, implantation of the stent resulted in iris touch, endothelial touch, or stent malposition less than 10% of the time. These events may decrease in frequency with surgeon experience. Steroid response occurred in 2 of 53 eyes and 5 weeks postoperatively in a case series. IOP was controlled after discontinuation of the steroids. The authors’ anecdotal experience suggests that steroid response can be significant with MIGS. We recommend an early taper of steroids in the majority of cases that do not develop significant postoperative inflammation.

Safety outcomes of the iStent inject were reported in two series. Interim analysis of patients who underwent
phacoemulsification with two implants yielded no loss of vision, hypotony, effusions, or anterior chamber shallowing.\textsuperscript{22} Endothelial cell count loss in these 20 eyes was 13%, although the mean loss of 302.7 cells/mm\textsuperscript{2} was accompanied by a high standard deviation of 288.7 cells/mm\textsuperscript{2}.\textsuperscript{20} In a different study where subjects were implanted with two injects in the absence of cataract surgery, elevated IOP necessitated either medical treatment or surgical intervention in the form of trabeculectomy, goniotrephanation, or deep sclerectomy in less than 5% within 1 year.\textsuperscript{11} In the same study, the incidence of stent obstruction and malposition was less than 5%.\textsuperscript{11} Interestingly, one of two of the devices were not visible upon postoperative gonioscopy in 13%, perhaps because of the small size or use of the original injector, which has since been updated. In a laboratory study of deliberately misplaced first-generation stents, Ichhpujani et al\textsuperscript{10} demonstrated that ultrasound biomicroscopy could reliably locate the stents, while anterior segment optical coherence tomography and B-scan ultrasonography could not. Future studies are needed to determine whether such imaging modalities can identify second-generation stents not visible under direct gonioscopy.

**Other considerations**

**Indications**

Trabecular micro-bypass stents are typically indicated for use in conjunction with cataract surgery in adults using ocular hypotensive drugs for mild to moderate open-angle glaucoma.\textsuperscript{3} While the above study populations have included POAG, PXG, PDG, traumatic glaucoma, steroid-induced glaucoma, OHT, and patients without cataract, POAG remains the most common indication. Contraindications include all forms of angle-closure glaucoma and post trabeculectomy causes of open-angle glaucoma.

No RCTs have examined trabecular micro-bypass stents in advanced open-angle glaucoma. Our opinion is that the use of multiple trabecular bypass stents may work well in more advanced glaucoma disease with reasonable or borderline preoperative IOP control. Furthermore, studies have not assessed the impact of the micro-bypass stent on IOP fluctuation, and so the benefit of the iStent in conditions where IOP fluctuation might play a more important role remains unclear.

**Cost**

As with many forms of treatment, cost will continue to play a major role in the uptake of the iStent. To date, one study has examined the cost of trabecular micro-bypass stents compared with other glaucoma treatments. Jordanus et al\textsuperscript{31} estimated the cumulative cost of two iStents versus medical therapy in Canada. Based on the Ontario Health Insurance Plan, the price of two stents plus disposable intraoperative materials excluding surgeon fees was approximated at Can$1,044 per patient. Over 6 years, cost savings of Can$20.77, Can$1,272.55, and Can$2,124.71 per patient were found when comparing two iStents versus monodrug, bidrug, and tridrug therapy, respectively. Similar savings were found with the Trabectome (NeoMedix, Tustin, CA, USA) and endoscopic cyclophotocoagulation compared with medication. The stents plus one medication still showed savings over bidrug or tridrug therapy, but stents with two eye drops were more expensive than tridrug therapy over time.\textsuperscript{31} It appears that the costs of trabecular stents are comparable to and possibly cost saving compared with alternatives in the short term. More data are required to evaluate long-term expenses and cost effectiveness.

**Quality of life**

Studies have yet to evaluate the effect of trabecular stents on quality of life. In the case of a successful surgical outcome, we may expect an improvement in quality of life due to reduction or elimination of glaucoma medications. Furthermore, avoiding or delaying the potential complications of more invasive glaucoma surgery may alleviate the negative impact of surgical glaucoma treatment on a patient’s quality of life.

**Phacoemulsification alone**

The IOP-lowering effect of phacoemulsification alone has been well documented. Long-term retrospective studies have observed reductions of 1–6 mmHg in POAG, normotensive glaucoma, glaucoma suspects, OHT, and normotensive patients without glaucoma.\textsuperscript{32,33} The trabecular micro-bypass RCTs discussed earlier found comparable ranges of IOP reduction in the phacoemulsification control arms.\textsuperscript{16,17} Suggested explanations include improved conventional outflow following a deepened anterior chamber, or decreased aqueous secretion from ciliary body traction via the zonules as the capsule contracts.\textsuperscript{32} What remains unknown is whether the hypotensive effect of phacoemulsification is synergistic with the iStent or is simply additive.

**MIGS**

Trabecular micro-bypass stents meet the criteria for MIGS: ab interno conjunctiva-sparing approach, minimal trauma
to the target tissue, efficacy, safety profile, and rapid recovery. The clear corneal incision spares the conjunctiva for future surgeries if necessary. The ab interno approach allows direct visualization of the angle, optimizing placement of the stents. Schlemm’s canal procedures enhance physiologic outflow pathways in the context of normal post trabecular pathways, thereby reducing IOP and dependency on medication. Furthermore, risks of serious and visually threatening complications associated with other glaucoma surgeries, such as hypotony, choroidal effusions, suprachoroidal hemorrhage, anterior chamber shallowing, and diplopia, are minimized.

Currently, MIGS act in the Schlemm’s canal, suprachoroidal space, or subconjunctival space. Devices that improve trabecular flow to Schlemm’s canal include the iStent, iStent inject, Trabectome,7,8,10,20,34,35 Eyepass (GMP Vision Solutions, Ft Lauderdale, FL, USA; no longer commercially available),16 and Excimer laser trabeculotomy (ELT; AIDA, TUI-Laser, Munich, Germany).5,9,35 To enhance flow within Schlemm’s canal, the Hydrus (Ivantis, Inc., Irvine, CA, USA)20,34,35 acts as a canalicular scaffold. To facilitate uveoscleral flow, the CyPass microstent (Transcend Medical, Menlo Park, CA, USA)34 or iStent supra (Glaukos Corporation) are implanted directly into the suprachoroidal space through an ab interno approach. The Aquesys (AquaSys Inc, Aliso Viejo, CA, USA),34 which is placed into the subconjunctival space, creates an alternative outflow pathway.

Clinical studies of trabecular devices have yielded successful IOP-lowering outcomes for open-angle glaucoma. The Trabectome, which uses electrocautery to strip the meshwork, has decreased IOP by a range of 4–7 mmHg and medications by one when combined with phacoemulsification in a number of studies.37–41 ELT, which uses photodisruption to create holes in the meshwork, has lowered IOP between 4 and 9 mmHg after 1 year in three studies.42–44 While individual treatment effects of some procedures have been compared with phacoemulsification, no studies have directly compared MIGS devices.

Conclusion

MIGS with the trabecular micro-bypass stent has been shown in numerous publications and large-scale studies to be a safe and effective procedure for mild to moderate open-angle glaucoma. The supportive evidence favoring the risk–benefit ratio of iStent implantation is most clear for concurrent phacoemulsification and iStent implantation in patients with mild to moderate open-angle glaucoma. Indications may expand to include patients with OHT, advanced glaucoma, and secondary open-angle glaucomas as more evidence becomes available for these conditions.

Disclosure

Dr Hady Saheb has received travel funding from Glaukos. The authors report no other conflicts of interest in this work.

References


